Dietmar W Siemann1, Wenyin Shi. 1. Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA. siemadw@ufl.edu
Abstract
BACKGROUND: This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents. MATERIALS AND METHODS: Human clear cell renal carcinoma (Caki-1) tumors were established in nude mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay. RESULTS: The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503. CONCLUSION: Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects.
BACKGROUND: This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents. MATERIALS AND METHODS:Humanclear cell renal carcinoma (Caki-1) tumors were established in nude mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay. RESULTS: The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503. CONCLUSION: Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects.
Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Dietmar W Siemann; Michael C Bibby; Graham G Dark; Adam P Dicker; Ferry A L M Eskens; Michael R Horsman; Dieter Marmé; Patricia M Lorusso Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Jianyi Hua; Yezhou Sheng; Kevin G Pinney; Charles M Garner; Robert R Kane; Joseph A Prezioso; George R Pettit; David J Chaplin; Klaus Edvardsen Journal: Anticancer Res Date: 2003 Mar-Apr Impact factor: 2.480
Authors: Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle Journal: Blood Date: 2010-05-14 Impact factor: 22.113
Authors: Chiao-Wang Sun; Li-Chen Wu; Mamta Wankhede; Dezhi Wang; Jutta Thoerner; Lawrence Woody; Brian S Sorg; Tim M Townes; David S Terman Journal: JCI Insight Date: 2019-02-19
Authors: Daniel J Inglis; Tina C Lavranos; Donna M Beaumont; Annabell F Leske; Chloe K Brown; Allison J Hall; Gabriel Kremmidiotis Journal: Cancer Biol Ther Date: 2014 Impact factor: 4.742